



[Case Report]

Human parechovirus infection mimicking septic shock and requiring critical care

Naoki Shimizu¹⁾, Eri Mineo^{1,2)}, Tadashi Kodani¹⁾ and Osamu Saito¹⁾

¹⁾ Department of Pediatric Emergency & Critical Care Medicine, Tokyo Metropolitan Children's Medical Center, Tokyo 183-8561. ²⁾ Department of Pediatrics, Kitasato University, Kanagawa 252-0375.

(Received May 10, 2018, Accepted August 1, 2018)

Abstract

Human parechovirus (HPeV), a potentially severe viral infection in infants and one of the chief causes of fever in young infants, typically presents fever, irritability, and rash, thus accounting for the patients' being described as "hot, red, angry babies". Treatment is primarily supportive and includes management of complications. Some infants with a severe HPeV infection may suffer adverse neurodevelopment, and follow-ups by a pediatrician are recommended. We experienced an infantile case of HPeV infection requiring critical care in which the interleukin-6 levels was not elevated. The immune response in HPeV infections is not fully understood and requires further study for clarification.

Key words: Severe sepsis, Septic shock, Interleukin, Cytokine, *Picornaviridae*

I . Introduction

Human parechovirus (HPeV) is an important cause of fever in young infants, who characteristically present with fever and irritability and occasionally also present a diffuse rash[1]. The severe form of the disease can lead to meningoencephalitis, seizure, sepsis-like presentations including septic shock as well as less common presentations including signs of surgical abdomen[2-7]. There are no effective antiviral therapies. Treatment is primarily supportive and includes management of complications. Some infants with a severe HPeV infection may show adverse

neurodevelopment, and follow-up by a pediatrician is recommended[8-10]. Hyper-cytokemia is suspected as the biochemical background of HPeV infections [11,12]. We experienced several infantile cases of HPeV infection and assessed their interleukin-6 levels.

II . Case

A 2-month-old boy visited a clinic due to high fever and poor feeding. He was previously healthy with no family history of infection. Sepsis was suspected, and he was transferred from the clinic to a local hospital. After multiple cultures were done, antibiotic treatment was begun. On day 2, during a brain MRI under sedation, the patient presented apnea leading to respiratory difficulty with foamy sputum. The MRI was discontinued, and the patient was intubated immediately. A chest XP and CAT scan revealed decreased permeability of the bilateral

Address correspondence to Dr. Naoki Shimizu.
Department of Pediatric Emergency & Critical Care Medicine,
Tokyo Metropolitan Children's Medical Center, 2-8-29,
Musashidai, Fuchu, Tokyo 183-8561, Japan.
Phone: +81-42-300-5111. Fax: +81-42-312-8160.
E-mail: naoki_shimizu@mac.com





Fig. 1 Chest XP and CAT scan of this case

- (a) XP
- (b) CAT scan

lungs (Fig. 1 (a), (b)). An echocardiogram disclosed an ejection fraction of 10%, and he was referred to our hospital for further treatment.

On admission to the pediatric ICU his vital signs showed tachycardia (HR over 180's/minute) and hypotension (systolic BP under 60's mmHg) while the blood gas analysis showed a high lactate level (over 5 mmol/dL). His clinical condition put him at risk of cardiogenic shock. Inotrope and lucinotrope (epinephrine and milrinone) were started. The spectrum of the antibiotics was broadened, and a high dose of corticosteroid for sepsis was administered. During the course of his ICU stay, he required intermittent use of high frequency oscillatory ventilation (HFOV) but was extubated on ICU day 9 and discharged from the ICU on day 10 (Fig. 2).




Fig. 2 Clinical course of this case in the pediatric ICU

The serum interleukin-6 (IL-6) level was measured in this case (ICU day 1) by RAY-FAST™ (TORAY Co., Ltd), however, IL-6 was not elevated.

III. Discussion

HPeV is increasingly being recognized as a potentially severe viral infection in infants. HPeV belongs to the family *Picornaviridae* and is currently divided into 19 genotypes[13]. HPeV-1 is the most prevalent genotype and commonly causes gastrointestinal and respiratory disease. HPeV-3 is clinically the most important genotype due to its association with severe disease states in younger infants, which may partly be explained by its distinct virological properties[14-16]. In young infants, the typical clinical presentation includes fever, irritability, and rash, which account for the description of the patients as “hot, red, angry babies”[1].

Although HPeV infection increases the risk of long-term neurological sequelae, the clinical course is self-limiting even when ICU admission is required. Molecular diagnosis for early detection should be included in the standard assessment for sepsis-like illnesses and general supportive critical care[17]. Early diagnosis is helpful for minimizing the unnecessary use of broad spectrum antibiotics, predicting the clinical course in the ICU, and preparing long-term, post-discharge neurological follow up.

Several studies suggested that the serum and/or cerebrospinal fluid (CSF) cytokine levels change in

HPeV infections. While Fortuna reported that CSF IL-6 and IL-8 were not elevated in HPeV cases[11], Yokota demonstrated that serum IL-6, IL-10, and interferon gamma were elevated in severe cases[12]. Fortuna measured cytokines levels comparing HPeV and enterovirus (EV), and he concluded that the immune response to HPeV infection differs from that of EV. Yokota measured cytokine levels in HPeV type 3 only. HPeV was known to have several genotypes[17], and type 3 is also known to be severe and show sepsis like clinical picture[5,6]. Our case showed no elevation of IL-6 on ICU day 1, however, we didn't analyze genotypes and this is one of our report limitations. The immune response in HPeV infections is not yet fully understood, and further research is needed for clarification.

Contributors

NS, EM, TK, and OS managed the case. TK measured IL-6. NS, EM, TK, and OS contributed to writing of the report. Consent to publication was obtained from the family. Publication was approved by the Institutional Review Board of Tokyo Metropolitan Children's Medical Center. Authors thank Mr. James Robert Valera for his assistance with editing the manuscript.

References

- 1) Britton PN, Jones CA, Macartney K, Cheng AC. (2018) Parechovirus: an important emerging infection in young infants. *Med J Aust* 208, 365-9.
- 2) de Jong EP, van den Beuken MGA, van Elzakker EPM, Wolthers KC, Sprij AJ, Lopriore E, Walther FJ, Brus F. (2018) Epidemiology of Sepsis-like Illness in Young Infants: Major Role of Enterovirus and Human Parechovirus. *Pediatr Infect Dis J* 37, 113-8.
- 3) Ollier V, Farfour E, Charara O, Marque Juillet S, Mirand A, Chalouhi C, Foucaud P. Severe human parechovirus-3 sepsis in a 6-week-old infant. (2014) *Arch Pediatr* 21, 399-401.
- 4) Schuffenecker I, Javouhey E, Gillet Y, Kugener B, Billaud G, Floret D, Lina B, Morfin F. (2012) Human parechovirus infections, Lyon, France, 2008-10: evidence for severe cases. *J Clin Virol* 54, 337-41.
- 5) Selvarangan R, Nzabi M, Selvaraju SB, Ketter P, Carpenter C, Harrison CJ. (2011) Human parechovirus 3 causing sepsis-like illness in children from Midwestern United States. *Pediatr Infect Dis J* 30, 238-42.
- 6) Harvala H, Wolthers KC, Simmonds P. (2010) Parechoviruses in children: understanding a new infection. *Curr Opin Infect Dis* 23, 224-30.
- 7) Abed Y, Boivin G. (2006) Human parechovirus types 1, 2 and 3 infections in Canada. *Emerg Infect Dis* 12, 969-75.
- 8) van Hinsbergh TMT, Elbers RG, van Furth MAM, Obihara CCC. (2018) Longitudinal association between human parechovirus central nervous system infection and gross-motor neurodevelopment in young children. *Pediatr Infect Dis J*. Mar 27 (Epub ahead of print).
- 9) de Jong EP, Holscher HC, Steggerda SJ, Van Klink JMM, van Elzakker EPM, Lopriore E, Walther FJ, Brus F. (2017) Cerebral imaging and neurodevelopmental outcome after entero- and human parechovirus sepsis in young infants. *Eur J Pediatr* 176, 1595-602.
- 10) Britton PN, Dale RC, Nissen MD, Crawford N, Elliott E, Macartney K, Khandaker G, Booy R, Jones CA, PAEDS-ACE Investigators. (2016) Parechovirus encephalitis and neurodevelopmental outcomes. *Pediatrics* 137, e20152848.
- 11) Fortuna D, Cárdenas AM, Graf EH, Harshyne LA, Hooper DC, Prosnik M, Shields J, Curtis MT. (2017) Human parechovirus and enterovirus initiate distinct CNS innate immune responses: pathogenic and diagnostic implications. *J Clin Virol* 86, 39-45.
- 12) Yuzurihara SS, Ao K, Hara T, Tanaka F, Mori M, Kikuchi N, Kai S, Yokota S. (2013) Human parechovirus-3 infection in nine neonates and infants presenting symptoms of hemophagocytic lymphohistiocytosis. *J Infect Chemother* 19, 144-8.
- 13) Olijve L, Jennings L, Walls T. (2017) Human parechovirus: an increasingly recognized cause of sepsis-like illness in young infants. *Clin Microbiol Rev* 31, pii: e00047-17.
- 14) Khatami A, McMullan BJ, Webber M, Stewart P, Francis S, Timmers KJ, Rodas E, Druce J, Mehta B, Sloggett NA, Cumming G, Papadakis G, Kesson AM. (2015) Sepsis-like disease in infants due to human parechovirus type 3 during an outbreak in Australia. *Clin Infect Dis* 60, 228-36.
- 15) Kolehmainen P, Jääskeläinen A, Blomqvist S, Kallio-Kokko H, Nuolivirta K, Helminen M, Roivainen M, Lappalainen M, Tauriainen S. (2014) Human parechovirus type 3 and 4 associated with severe infections in young children. *Pediatr Infect Dis J* 33, 1109-13.
- 16) Esposito S, Rahamat-Langendoen J, Ascolese B, Senatore L, Castellazzi L, Niesters HG. (2014) Pediatric parechovirus infections. *J Clin Virol* 60, 84-9.
- 17) Benschop K, Molenkamp R, van der Ham A, Wolthers K, Beld M. (2008) Rapid detection of human parechoviruses in clinical samples by real-time PCR. *J Clin Virol* 41, 69-74.